Amicus Therapeutics Partners with Dimerix Amid Financial Challenges, Eyes Growth with DMX-200
Amicus Therapeutics navigates financial challenges in Q1 2025, but reports revenue growth and a strategic partnership with Dimerix to advance its pipeline and address rare kidney disease FSGS.
2 minutes to read